FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Prelude Therapeutics Incorporated Stock AnalysisComprehensive stock analysis for Prelude Therapeutics Incorporated (PRLD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPRLD
PRLD
Prelude Therapeutics Incorporated
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PRLD
Home🔹Stocks🔹Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

PRLD•NASDAQ

Prelude Therapeutics Incorporated

PRLD•NASDAQ
Market cap
$264.17M
Sentiment

Your view on PRLD

Mkt Cap
$264.17M
Sentiment
Your view
PRLD
Prelude Therapeutics Incorporated
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PRLD
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Prelude Therapeutics Incorporated

Industry
Biotechnology
Sector
Healthcare
CEO
Krishna Vaddi
Headquarters
200 Powder Mill Road, Wilmington, DE, US
Industry
Biotechnology
Sector
Healthcare
CEO
Krishna Vaddi
Headquarters
200 Powder Mill Road, Wilmington, DE, US
Description

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News